SCHEMBL26606502

SCHEMBL26606502

O=Cc1ccc(C(=O)Nc2nc3ccccc3s2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.74
RAB9A P51151 6/20 0.74
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
SCD O00767 7/20 0.71
KDM4E B2RXH2 5/20 0.71
HTT P42858 2/20 0.71
NFKB1 P19838 2/20 0.71
NFKB2 Q00653 2/20 0.71
RELA Q04206 2/20 0.71
MMP13 P45452 1/20 0.65
TOP1 P11387 2/20 0.64
CASP3 P42574 2/20 0.62
SENP8 Q96LD8 2/20 0.62
SENP7 Q9BQF6 2/20 0.62
SENP6 Q9GZR1 2/20 0.62
LRRK2 Q5S007 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.59
MAPT P10636 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30576829 1.00 NPC1 (0.74) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3053529 0.86 NPC1 (1.00) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL16562172 0.85 NPC1 (0.86) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4915099 0.83 NPC1 (1.00) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL30553332 0.83 NPC1 (0.78) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4920257 0.83 NPC1 (0.78) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4917567 0.83 NPC1 (1.00) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL16562119 0.83 NPC1 (0.80) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL6687151 0.83 SCD (1.00) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4910843 0.83 NPC1 (0.78) NPC1RAB9AMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-04-11 US disclosed
EP-4269394-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2023-11-01 EP disclosed
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 CN disclosed
WO-2022164135-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT SIRT7, SIRT1, BRD7 NPC1 1296/4885RAB9A 2738/4885MEN1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.